EUROPEAN VCS still have a pulse for early-stage deals, and are in sharp contrast to US VCs who have migrated to a myopic focus on digital health. Not only are European VCs investing early, they are also doing so in biotech and biopharma companies at a preclinical stage, which has not happened in the US for many years. European deals are also still very significantly undervalued. ”
”
http://m.mddionline.com/node/10902?cid=nl.mddi01
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022